2024-12-28 03:27:36
CStone Pharmaceuticals Announces China's NMPA has Accepted its New Drug Application for anti-PD-L1 Monoclonal Antibody Sugemalimab in First-Line Advanced NSCLC
Corporate/ 2023-07-23
CStone Pharmaceuticals Announces China&#...

Currently,there is no anti-PD-L1 monoclonal antibody approved for stage IV NSCLC in China An oral presentation of specific clinical trial da...

I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting
Corporate/ 2023-07-23
I-Mab Reports Phase 1 Clinical Trial Dat...

SHANGHAI and GAITHERSBURG,Md.,Nov. 9,2020--I-Mab (the "Company") (Nasdaq: IMAB),a clinical stage biopharmaceutical company committ...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release